Article Details
Retrieved on: 2025-01-23 20:56:14
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article explores the broader benefits and risks of GLP-1 receptor agonists, like Ozempic, in treating obesity, cognitive decline, addiction, and potentially reducing COVID-related cardiovascular risks. The drugs initially target diabetes management.
Article found on: globelynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here